Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool?
Jacob M Sands1, Marina S D Milan1, Geoffrey R Oxnard1
1Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
No abstract available in PubMed .


